BioSpace News Archive

Melbourne biotech company Starpharma has announced the publication of new data demonstrating the capability of its Viraleze antiviral nasal spray to protect against SARS-CoV-2 in an animal challenge model of SARS-CoV-2 infection[1].

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Gerald Commissiong, CEO of Todos Medical, is scheduled to appear on Varney & Co. on the Fox Business Network at 11:40 AM Eastern Time today.

BELLUS Health Inc. announced that an abstract covering additional data from the RELIEF Phase 2a trial has been accepted for oral presentation at the upcoming European Respiratory Society International Congress 2021, being held September 5-8, 2021.

Vivos Therapeutics, Inc today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance to Vivos’ mmRNA device for treating mild to moderate OSA, sleep-disordered breathing and snoring in adults.

Athira Pharma, Inc. today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer’s drug development

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced that PRESIDIO, its Phase 2 clinical trial to evaluate the safety and efficacy of KZR-616 for the treatment of polymyositis and dermatomyositis completed the target enrollment of 24 subjects.

Samyang Biopharm USA, Inc. a global biotech subsidiary of the Samyang Holdings Pharmaceuticals Corp., announced that the company has entered into a three-year research collaboration with Dr. Hyun-Sung Lee, Assistant Professor of Surgery and Director of the Systems Onco-Immunology Laboratory at Baylor College of Medicine.

Acerus Pharmaceuticals Corporation today announced that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15 in New York.

AnPac Bio-Medical Science Co., Ltd. today announces that the Company filed with China’s National Medical Products Administration (NMPA) on Aug. 19, 2021, for registration testing of its class III, multi-cancer detection medical device based on its Cancer Differentiation Analysis Technology (CDA).